Wesley Tanaka

4.2k total citations
33 papers, 2.8k citations indexed

About

Wesley Tanaka is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Physiology. According to data from OpenAlex, Wesley Tanaka has authored 33 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Physiology. Recurrent topics in Wesley Tanaka's work include Asthma and respiratory diseases (7 papers), Eicosanoids and Hypertension Pharmacology (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Wesley Tanaka is often cited by papers focused on Asthma and respiratory diseases (7 papers), Eicosanoids and Hypertension Pharmacology (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Wesley Tanaka collaborates with scholars based in United States, Belgium and Japan. Wesley Tanaka's co-authors include Karen Snyder, Michael Tanen, Gary Herman, Arthur Bergman, Bingming Yi, Omar Laterza, Jason M. Johnson, Joseph F. Sina, Kateřina Vlasáková and Philip W. Garrett-Engele and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Analytical Biochemistry and Clinical Cancer Research.

In The Last Decade

Wesley Tanaka

33 papers receiving 2.6k citations

Peers

Countries citing papers authored by Wesley Tanaka

Since Specialization

Citations

This map shows the geographic impact of Wesley Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wesley Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wesley Tanaka more than expected).

Fields of papers citing papers by Wesley Tanaka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wesley Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wesley Tanaka. The network helps show where Wesley Tanaka may publish in the future.

Co-authorship network of co-authors of Wesley Tanaka

This figure shows the co-authorship network connecting the top 25 collaborators of Wesley Tanaka. A scholar is included among the top collaborators of Wesley Tanaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wesley Tanaka. Wesley Tanaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quantitative measurement of cysteinyl leukotrienes and leukotriene B4 in human sputum using ultra high pressure liquid chromatography–tandem mass spectrometry 2010 ·Journal of Chromatography B ·(unknown), (unknown), (unknown), (unknown), Stuart Green, Wesley Tanaka, Omar Laterza	18
2	A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology 2007 ·Analytical Biochemistry ·Suzanne S. Eveland, Denise P. Milot, Qiu Guo, Ying Chen, Sheryl A. Hyland, Laurence B. Peterson, (unknown), (unknown), Paul Zuck, Marc Ferrer, Berta Strulovici, John A. Wagner, Wesley Tanaka, Deborah Hilliard, Omar Laterza, Samuel D. Wright, Carl P. Sparrow, Matt S. Anderson	13
3	Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults 2007 ·The Journal of Clinical Endocrinology & Metabolism ·Ira Gantz, Ngozi Erondu, Madhuja Mallick, Bret J. Musser, Rajesh Krishna, Wesley Tanaka, Karen Snyder, (unknown), Mark Stroh, Haiyuan Zhu, John A. Wagner, Douglas J. MacNeil, Steven B. Heymsfield, John M. Amatruda	124
4	Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects 2006 ·The Journal of Clinical Pharmacology ·Gary Herman, Arthur Bergman, Fang Liu, (unknown), Amy Q. Wang, Wei Zeng, Li Chen, Karen Snyder, Deborah Hilliard, Michael Tanen, Wesley Tanaka, Alan G. Meehan, Kenneth C. Lasseter, Stacy C. Dilzer, Robert A. Blum, John A. Wagner	146
5	A Dual PPAR ??/?? Agonist Increases Adiponectin and Improves Plasma Lipid Profiles in Healthy Subjects 2006 ·Drugs in R&D ·Katelijn Decochez, (unknown), Jutta Miller, Marina De Smet, (unknown), (unknown), Kerry Riffel, (unknown), Haiyuan Zhu, (unknown), Wesley Tanaka, Amy O. Johnson‐Levonas, Michael J. Davies, Keith Gottesdiener, Bart Keymeulen, John A. Wagner	16
6	Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers 2006 ·Clinical Therapeutics ·Arthur Bergman, (unknown), Yanyan Zhou, Bingming Yi, Martine E. Laethem, Marina De Smet, Karen Snyder, Deborah Hilliard, Wesley Tanaka, Wei Zeng, Michael Tanen, Amy Q. Wang, Li Chen, Gregory A. Winchell, Michael J. Davies, Steven Ramael, John A. Wagner, Gary Herman	220
7	Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses 2005 ·Clinical Pharmacology & Therapeutics ·Gary Herman, C. Melinda Stevens, Koen Vandyck, Arthur Bergman, Bingming Yi, (unknown), Karen Snyder, D Hilliard, Michael Tanen, Wesley Tanaka	414
8	Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration 1999 ·Inflammation Research ·Aimée Dallob, Inge De Lepeleire, Anne Van Hecken, Arturo G. Porras, Marleen Depré, Saurabh Mukhopadhyay, (unknown), (unknown), Keith Gottesdiener, Wesley Tanaka, P. De Schepper	6
9	Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist 1997 ·Thorax ·Theodore F. Reiss, (unknown), Eloise Harman, J. Zhang, Wesley Tanaka, Edwin A. Bronsky, D. Guerreiro, Leslie Hendeles	170
10	MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen¹ 1997 ·The Journal of Clinical Endocrinology & Metabolism ·Jules I. Schwartz, Wesley Tanaka, (unknown), David L. Ebel, (unknown), Aimée Dallob, Barry Hafkin, Barry J. Gertz	30
11	MK-386, an Inhibitor of 5 alpha-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum Without Affecting Dihydrotestosterone Concentrations in Semen 1997 ·Obstetrical & Gynecological Survey ·Jules I. Schwartz, Wesley Tanaka, (unknown), David L. Ebel, (unknown), Aimée Dallob, Barry Hafkin, Barry J. Gertz	9
12	Comparison of the effects of new specific azasteroid inhibitors of steroid 5α‐reductase on canine hyperplastic prostate: Suppression of prostatic DHT correlated with prostate regression 1995 ·The Prostate ·Sheila M. Cohen, (unknown), Gary H. Rasmusson, Wesley Tanaka, (unknown), G. Harris, (unknown), (unknown), T. M. Nett	37
13	Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase—activating protein inhibitor 1994 ·Clinical Pharmacology & Therapeutics ·(unknown), Beth S. Friedman, Anne Van Hecken, Inge De Lepeleire, Wesley Tanaka, Aimée Dallob, Sumiko Shingo, Arturo G. Porras, Charles C. Lin, P.J. De Schepper	16
14	The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. 1994 ·The Journal of Clinical Endocrinology & Metabolism ·(unknown), Neil S. Sadick, Walter Unger, (unknown), (unknown), (unknown), Ha Nguyen, E. Colleen Moore, Wesley Tanaka	159
15	Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans 1993 ·Clinical Pharmacology & Therapeutics ·Marleen Depré, Beth S. Friedman, Wesley Tanaka, Anne Van Hecken, A. Buntinx, Paul J. DeSchepper	18
16	The effect of mk-591, a potent oral leukotriene biosynthesis inhibitor, on allergen-induced airway responses in asthmatic subjects 1993 ·American Review of Respiratory Disease ·Zuzana Diamant, (unknown), (unknown), (unknown), (unknown), Wesley Tanaka, Marleen Depré, (unknown), (unknown), PJ Sterk	5
17	High-performance liquid chromatographic determination of PZ-peptidase activity 1993 ·Journal of Chromatography A ·Toshiyuki Chikuma, Wesley Tanaka, Kanae Yamada, Yoko Ishii, Akira Tanaka, (unknown)	4
18	Oral Leukotriene Inhibitor (MK-886) Blocks Allergen-induced Airway Responses 1993 ·American Review of Respiratory Disease ·Beth S. Friedman, (unknown), A. Buntinx, Wesley Tanaka, (unknown), Sumiko Shingo, Reynold Spector, Peter J. Sterk	126
19	Clinical and Biochemical Effects of an Oral Leukotriene Biosynthesis Inhibitor (MK886) in Psoriasis 1991 ·Skin Pharmacology and Physiology ·E.M.G.J. de Jong, (unknown), (unknown), A. Buntinx, (unknown), Wesley Tanaka, P.C.M. van de Kerkhof	18
20	Subcellular Distribution of Aminoacyl‐tRNA Synthetases in Various Eukaryotic Cells 1977 ·European Journal of Biochemistry ·Michael A. Ussery, Wesley Tanaka, Britta Denise Hardesty	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact